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838Cotransplantation of Mesenchymal Stem Cells Might
Prevent Death from Graft-versus-Host Disease (GVHD)
without Abrogating Graft-versus-Tumor Effects after
HLA-Mismatched Allogeneic Transplantation following
Nonmyeloablative Conditioning
Frederic Baron,1,2,3 Chantal Lechanteur,2,3 Evelyne Willems,1,2 France Bruck,2
Etienne Baudoux,1,3 Laurence Seidel,4 Jean-Franc¸ois Vanbellinghen,5 Kaoutar Hafraoui,1
Marie Lejeune,1 Andre Gothot,2,6 Georges Fillet,1,2,3 Yves Beguin1,2,3Recent studies have suggested that coinfusion of mesenchymal stem cells (MSCs) the day of hematopoietic
cell transplantation (HCT) might promote engraftment and prevent graft-versus-host disease (GVHD) after
myeloablative allogeneic HCT. This prompted us to investigate in a pilot study whether MSC infusion before
HCT could allow nonmyeloablative (NMA) HCT (a transplant strategy based nearly exclusively on graft-
versus-tumor effects for tumor eradication) from HLA-mismatched donors to be performed safely. Twenty
patients with hematologic malignancies were given MSCs from third party unrelated donors 30-120 minutes
before peripheral blood stem cells (PBSCs) fromHLA-mismatched unrelated donors, after conditioning with
2 Gy total body irradiation (TBI) and fludarabine. The primary endpoint was safety, defined as a 100-day
incidence of nonrelapse mortality (NRM)\35%. One patient had primary graft rejection, whereas the re-
maining 19 patients had sustained engraftment. The 100-day cumulative incidence of grade II-IV acute
GVHD (aGVHD) was 35%, whereas 65% of the patients experienced moderate/severe chronic GVHD
(cGVHD). One-year NRM (10%), relapse (30%), overall survival (OS) (80%) and progression-free survival
(PFS) (60%), and 1-year incidence of death from GVHD or infection with GVHD (10%) were encouraging.
These figures compare favorably with those observed in a historic group of 16 patients given HLA-
mismatched PBSCs (but no MSCs) after NMA conditioning, which had a 1-year incidence of NRM of 37%
(P5 .02), a 1-year incidence of relapse of 25% (NS), a 1-year OS and PFS of 44% (P5 .02), and 38% (P5 .1),
respectively, and a 1-year rate of death from GVHD or infection with GVHD of 31% (P5 .04). In conclusion,
our data suggest that HLA-mismatched NMA HCTwith MSC coinfusion appeared to be safe.
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Allogeneic hematopoietic cell transplantation
(HCT) following nonmyeloablative (NMA) condi-
tioning has been an effective treatment for many
patients with hematologic malignancies who have an
HLA-matched related or unrelated donor [1-10].
However, results of NMA HCT in patients with
HLA-mismatched donors have been less favorable be-
cause of a high incidence of graft rejection and severe
acute graft-versus-host disease (aGVHD) [4,5,11-13].
NMA HCT relies nearly exclusively on graft-versus-
tumor (GVT) effects for tumor eradication, which
has been closely correlated with both achievement of
full donor T cell and natural killer (NK) cell chimerism
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[14,18-21].
Mesenchymal stem cells (MSCs) are multipotent
progenitors within the bone marrow (BM) capable of
differentiating into various cells and tissues, such as
chondrocytes, osteoblasts, and adipocytes [22]. In vi-
tro, MSCs support hematopoiesis, and inhibit T cell
proliferation [23], NK cell cytotoxicity [24], and den-
dritic cell differentiation [25,26]. In animal models,
coinfusion of MSCs has been shown to facilitate
engraftment of human cord blood CD341 cells in
nonobese diabetic/severe combined immunodeficient
(NOD/SCID) mice [27], to prolong skin allograft sur-
vival in baboons [28], and to prevent aGVHD in some
mice models [29] as well as in a xenogeneic (human
into NOD/SCID mice) models of aGVHD [30], per-
haps by promoting the generation of regulatory T cells
[29,31]. In addition, phase II studies in humans have
demonstrated that MSC infusions were safe [32-34],
and might accelerate lymphocyte recovery and
prevent graft failure after haploidentical HCT [35].
Further, MSC infusions have also shown promising
efficacy in patients with steroid-refractory aGVHD
[36], although a recent industry-sponsored trial failed
to shown improvement of survival by MSCs in
that setting [37]. These observations prompted us to
investigate whether MSC infusion 0.5 to 2 hours
before HCT could allow NMA HCT from HLA-
mismatched donors to be performed safely (defined
as a 100-day incidence of nonrelapse mortality
[NRM]\35%). Because MSCs coinfusion has been
shown to promote tumor growth in a mice study
[38], and has been associated with a significantly in-
creased relapse rate in 1 human study [39], an impor-
tant additional focus of our study was to examine the
impact of MSC coinfusion on cGVHD, and more im-
portantly on GVT effects.PATIENTS AND METHODS
Eligibility Criteria
Patients
Patients older than 55 years of age, and those with
comorbid conditions precluding myeloablative condi-
tioning were eligible for the study if they had 1 of the
following hematologic malignancies: acute leukemia
in complete remission, chronic myelogenous leukemia
unresponsive to imatinib (or imatinib intolerance) but
not in blast crisis, myeloproliferative disorder not in
blast crisis and not with extensive myelofibrosis, mye-
lodysplastic syndrome with\5%BMblasts at the time
of HCT, high risk multiple myeloma (MM), chronic
lymphocytic leukemia, or lymphoma. Exclusion
criteria included HIV seropositivity, age of.75 years,
terminal organ failure except for renal failure(dialysis acceptable), uncontrolled infection, arrhyth-
mia or hypertension, previous radiation therapy pre-
cluding the use of 2 Gy total body irradiation (TBI),
and presence of a HLA-matched donor fit to donate
PBSC.
PBSC donors
Related or unrelated donors who had 1-2 HLA
mismatches, as either: 1 antigenic mismatch at HLA-A
or -B or -C or -DRB1 or -DQB1; 1 allelic mismatch at
HLA-A or -B or -C or -DRB1 or -DQB1; 2 allelic mis-
matches at HLA-A or -B or -C or -DRB1 or -DQB1;
1 antigenic mismatch 6 1 allelic mismatch at HLA-A
or -B or -C or -DRB1 or -DQB1; 1 antigenic mis-
match at -DQB1 and 1 other antigenic mismatch at
HLA-A or -B or -C or -DRB1 could serve as periph-
eral blood stem cell (PBSC) donor. Compatibility
between donor and recipient for HLA-A, -B, -C,
-DR, and -DQ was assessed by high-resolution tech-
niques. Only PBSCs were allowed as stem cell source.
Unrelated PBSCs were collected according to the pro-
cedures of the respective National Donor Registries.
MSC donors
Inclusion criteria for MSC donors included:
related (sibling, parent, or child) or unrelated to the
recipient (all MSC donor in the current study were
actually unrelated to the recipients); aged .16 years;
no HLA matching required; fulfilled generally
accepted criteria for allogeneic HSC donation; and
informed consent given. Exclusion criteria included:
HIV seropositivity, known allergy to lidocaine, and
any risk factor for transmissible infectious diseases.
Compatibility between MSC donor, PBSC donor,
and recipient for HLA-A, -B, -C, -DR, and -DQ was
assessed by low-resolution techniques.
The protocol was approved by the local Ethics
Committee and by the Belgian Federal Agency for
Medicines and Health Products (Eudract # 2006-
004101-26). Written informed consent was obtained
for each patient and MSC donor. The study was
also registered to ClinicalTrials.gov (protocol #
NCT00504803).MSC Preparation
MSC expansion cultures were performed at the
University of Lie`ge as described by other groups of
investigators [36]. Briefly, BM (30-50 mL) was col-
lected under local anesthesia in sterile conditions,
and put in sterile heparin-containing syringes. Mono-
nuclear BM cells were isolated by Ficoll (GE
Healthcare-Amersham Biosciences AB, Upsala, Swe-
den), seeded in sterile tissue culture flasks (BD
Falcon, Bedford, MA), and cultured in Dulbeccos
Modified Eagles Medium-Low Glucose (Invitrogen,
Merelbeke, Belgium) with glutamate supplemented
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Perbio Science, Merelbeke, Belgium) and antibiotics
(penicillin/streptomycin, Lonza Bio Science, Verviers,
Belgique). Cultures were maintained at 37 C in
humidified atmosphere containing 5% CO2 for a total
of about 4 weeks. The medium was replaced twice
a week and, after approximately 2 weeks, the cultures
were near confluence (.70%). Cells were then
detached by treatment with irradiated trypsin-EDTA
(Invitrogen, Merelbeke, Belgium) and replated (pas-
saged) at a lower density to allow further expansion. A
second passage was performed when the cells reached
again confluence (.70%). After a sufficient 2 passages,
the cells were harvested, washed, and resuspended us-
ing phosphate-buffered saline (PBS)-EDTA (Miltenyi
Biotec, Utrecht, The Netherlands) and Human Serum
Albumin (HSA) (CDF-CAF, Bruxelles, Belgique).
MSCs were then frozen in a medium containing 70%
PBS, 20% HSA, and 10% DMSO (WAK-Chemie,
Steinbach, Germany) by standard techniques. Before
infusion, MSCs were thawed and diluted in PBS, and
then injected into the patients 30-120 minutes before
PBSCs. All reagents were certified sterile, and
endotoxin-free, and had been used in other clinical tri-
als in Europe. In addition, the batch of fetal bovine
serum used was selected after extensive testing, and
was irradiated to ensure removal of all potential viruses.
The following analyses were performed as quality con-
trols for each MSC expansion culture: nucleated cell
count on amanual cell counter, flow cytometry analysis
with determination of the % cells (on total cells)
positive for CD73, CD90, and CD105, and negative
for HLA-DR, CD31, CD80, CD14, CD45, CD3,
and CD34; cell viability by trypan blue exclusion;
microbiology testing, including standard virology, bac-
terial culture, and search for mycoplasma; endotoxin
detection by the limulus test; and cytogenetics.
Further, MSC differentiation into adipocytes, osteo-
cytes, and chondrocytes as well as inhibitory effects of
MSCs on T cell function were validated in preliminary
experiments, and verified after some MSC expansion.
In the current study, MSC donors were third-party
unrelated to the recipient and to the PBSC donor in
all cases.Conditioning Regimen, HCT, and Post-HCT
Follow-up
The conditioning regimen consisted of Flu 30 mg/
m2 on days24,23, and22 (total dose 90 mg/m2), fol-
lowed by a single dose of 2GyTBI administered on day
0 before infusion of cells. MSCs were infused first, fol-
lowed by PBSCs infused at least 30-120 minutes later.
Mycophenolatemofetil (MMF)was administeredorally
from the evening of day 0 through day 42 at the dose of
15mg/kg three times a day.Tacrolimuswas givenorally
at the dose of 0.06mg/kg twice a day starting on day –3.The dose was then adapted according to throughwhole
blood values between 15 and 20 ng/mL thefirst 28 days,
and between 10 and 15 thereafter. Full doses were given
until day 180. Doses were then progressively tapered to
be definitely discontinued by day 365 in the absence of
GVHD. Tacrolimus was discontinued earlier in case of
disease progression or graft rejection, in patients with-
out disease response on day 100, and in those with
very-high risk disease. Tacrolimus was continued lon-
ger in case of cGVHD.
The diagnosis, clinical grading, and treatment of
aGVHDwere performed according to established cri-
teria for NMAHCT [14,40]. Diagnosis and grading of
cGVHDwere performed using the National Institutes
of Health (NIH) consensus criteria [41]. Treatment
was given for grade II-IV aGVHD and for extensive
cGVHD. Initial treatment usually consisted of pred-
nisolone, 1-2 mg/kg/day, with taper initiated within
14 days. In addition, tacrolimus was usually resumed
at full doses. Steroid-refractory aGVHD was treated
as per available investigational protocols or standard
practice. Treatment of cGVHD consisted of methyl-
prednisolone (1 mg/kg) with alternate-day tacrolimus.
Steroid-refractory cGVHD was generally treated with
rapamycine, MMF, or photophoresis.
Standard prophylaxis against infections was used
[42]. Disease evaluation was routinely carried out on
days 40, 100, 180, 365, and then at least yearly thereaf-
ter. Persistent, progressive or relapsed malignancies in
the absence of severe manifestation of GVHD were
treated by rapid taper and discontinuation of immuno-
suppression to initiate GVT effects, and with chemo-
therapy with or without added antimyeloma agents
such as thalidomide, lenolidomide, or bortezomib
according to the underlying disease.
Chimerism Analyses
Chimerism among T cells and total white blood or
BM cells was assessed on days 28, 42, 100, 180, and 365
after HCT using PCR-based analysis of polymorphic
microsatellite regions (AmpFlSTR Identifiler, Ap-
plied Biosystems, Lennik, Belgium). CD3 (T cells) se-
lection was carried out with the RosetteSep lymphoid
enrichment kit (StemCell Technologies, Grenoble,
France). Graft rejection was defined as the occurrence
of\5% T cells of donor origin after HCT, as previ-
ously described [3,15]. Numbers of T cells of donor
origin were calculated by multiplying the absolute
numbers of CD31 T cells by the % of T cells of
donor origin (chimerism) on the same day.
Historic Group
Sixteen consecutive patients given HLA-
mismatched unmanipulated PBSCs from unrelated
donors following Flu and 2 Gy TBI between May
2002 and August 2006 were included in a historic
Biol Blood Marrow Transplant 16:838-847, 2010 841MSC after Nonmyeloablative Conditioningcontrol group (we thus excluded patients given HLA-
mismatched CD8-depleted PBSCs [5] and those con-
ditioned with 4 Gy TBI, to have a historic group as
comparable as possible to the study group). Their di-
agnosis included MM (n 5 6), follicular lymphoma
(n 5 3), mantle cell lymphoma (n 5 2), acute myelog-
enous leukemia (AML) in complete remission (n5 2),
myelodysplastic syndrome (refractory anemia n 5 1,
refractory anemia with excess of blasts n 5 1), and re-
nal cell carcinoma (n 5 1) (Table 1). Median patient
age was 55 years (range: 10-69 years). Eleven pairs
were mismatched for at least 1HLA antigen (including
3 pairs who were also mismatched for another HLA
antigen [n 5 1], or another HLA allele [n 5 2]),
whereas 5 pairs were mismatched for a single HLA
class I (n 5 2) or HLA class II (n 5 3) alleles. Median
HCT-comorbidity index (HCT-CI) score [43] was 3
(range: 0-6). Median number of transplanted CD341
and CD31 T cells were 4.1 (range: 1.5-20.2)  106/
kg recipient and 313 (range: 159-790)  106/kg recip-
ient, respectively. Postgrafting immunosuppression
and infection prophylaxis was similar to what was
done in the MSC group. Specifically, postgrafting im-
munosuppression included MMF administered orallyTable 1. Characteristics of Patients and HCTOutcomes
Number of patients
Age; median (range), years
Gender (male/female); No. of patients
Disease at transplantation; No. of patients
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Non-Hodgkin lymphoma
Hodgkin lymphoma
Myelodysplastic syndrome
Multiple myeloma
Plasmablastic leukaemia
Metastatic renal cell carcinoma
Disease risk*: low / standard / high ; No. of patients
Patient/donor compatibility; No. of patients
$1 HLA-antigen mismatch
2 HLA-allele mismatches
1 HLA-allele mismatches
Comorbidities (HCT-CI score†); median (ranges)
Karnofsky score; median (ranges)
Prior autologous HCT, No. of patients
No. of cells transplanted (106/kg); median (range)
CD34+ cells
CD3+ cells
Graft rejection‡; No. of patients
Number of T cells of donor origin on day 28; median (range)
Incidence of grade II-IV acute GVHD (%)
Grade IV acute GVHD, # of patients (%)
1-year probability of dying from GVHD or infection while on treatment for
GVHD (%)
1-year nonrelapse mortality (%)
1-year relapse incidence (%)
1-year progression-free survival (%)
1-year overall survival (%)
GVHD indicates graft-versus-host disease; HCT, hematopoietic cell transplant
*-reference #45.
†-reference #43.
‡-occurrence of <5% T cell of donor origin after HCT.from the evening of day 0 through day 42 at the dose
of 15 mg/kg three times a day. Tacrolimus (n 5 5) or
cyclosporine (n 5 11) were given orally at full doses
until day 180, and then progressively tapered to be def-
initely discontinued by day 365.Statistical Analyses
Results were analyzed as of October 23, 2009.
Survival and progression-free survival were estimated
by the Kaplan-Meiermethod. Cumulative incidence es-
timates for GVHD, relapse, NRM, death fromGVHD
or infection while on treatment for GVHD, and graft
rejection were calculated using methods previously
described [44]. The primary endpoint was to study the
feasibility and safety (defined as a day 100 incidence of
NRM #35%) of NMA HCT with coinfusion of
MSCs andHLA-mismatchedPBSCs.Therewas a stop-
ping rule for evidence for NRM .35%. The impact of
MSC cotransplantation on survival, relapse, and
treatment-related mortality was assessed in multivariate
Coxmodels adjusted for typeofHLAmismatch (1 single
allele versus.1 single allele), comorbidity [43], disease
risk [45], and patient age. Statistical analyses wereMSC Group Historic Group P Value
20 16 NS
58 (21-69) 55 (10-69) NS
14 / 6 13 / 3 NS
7 2
1 0
5 5
1 0
0 2
5 6
1 0
0 1
6 / 11 / 3 7 / 4 / 5 NS
NS
13 11
1 0
6 5
3 (0-9) 3 (0-6) NS
90 (50-90) 90 (70-90) NS
10 9 NS
4.8 (1.6-11.8) 4.1 (1.5-20.2) NS
312 (120-540) 313 (159-790) NS
1 0 NS
293 (4-540) 202 (41-886) NS
45 56 NS
2 (10) 3 (19) NS
10 31 .04
10 37 .02
30 25 NS
60 38 .1
80 44 .02
ation; msc, mesenchymal stem cell; HCT-CI, HCT-comorbidity index.
Table 2. Detailed Patients, Donors and HCT Characteristics in the MSC Group (All Patients Were Given Grafts from Unrelated Donors)
Pt No.
Pt Age
(Years)/Gender
Disease/Status
at HCT
Indication for
Allogeneic HCT
HCT-CI
Score /KS
Donor Age
(Years)/ Gender
M/M in Rejection
Direction
M/M in GVHD
Direction
No. CD34
Transplanted (106/ kg)
No. CD3
Transplanted (106/ kg)
1 58 / F MM / PR 7 prior lines of q including 2 auto-HCT 1/ 70 41 / M 0 DQBI (1Al) 11.8 312
2 41 / F CLL / PR Del 17p, refractory to fludarabine-cyclophosphamide 3 / 100 50 / M C (1Ag) C (1 Ag) 4.3 266
3 65 / F AML / CR1 FLT3-ITD 0 / 100 44 / F C (1Ag) C (1 Ag) 2.1 350
4 58 / M MM / VGPR 2 auto-HCT 3 / 100 37 / M C (1Ag) C (1 Ag) 8.1 222
5 65 / M PL / CR1 2 auto-HCT 3 / 80 29 / M C (1Ag) C (1 Al) 3.1 164
6 43 / M NHL-T / CR1 1 auto-HCT 3 / 90 19 / M C (1Ag) 0 1.6 121
7 61 / M AML / CR1 Secondary to extended field radiotherapy for seminoma 4 / 90 36 / F DRB1 (1 Al) DRB1 (1 Al) 7.1 364
8 21 / M AML / CR2 ARDS, prior HCT, invasive lung aspergilosis at HCT 4 / 80 36 / M DQB1 (1 Al) DRB1 (1 Al) 6.3 540
9 61 / M AML / CR2 Del 7q, auto-HCT 2 / 90 43 / M C (1Ag) C (1 Ag), DQBI (1Ag) 6.4 390
10 56 / F AML / CR1 Secondary to chemoradiotherapy for breast cancer 6 / 50 42 / M C (1Ag) C (1 Ag)
DRB1 (1 Al)
DQB1 (1 Al)
4.7 297
11 64 / M NHL-F / ref. 5 prior lines of q including auto-HCT 0 / 90 50 / F C (1Ag) C (1 Ag) 7.8 429
12 55 / M AML / CR1 Secondary to chemo-radiotherapy for sarcoma 9 / 80 22 / M DQBI (1 Al) DQBI (1 Al) 2.6 275
13 69 / M MCL / CR1 Failure of autologous PBSC mobilisation 1 / 90 41 / M B (1 Al) B (1 Al) 5.1 354
14 60 / M DLBCL / CR2 Failure of autologous PBSC mobilisation 3 / 80 43 / M C (1Ag) C (1 Ag) 3.8 408
15 30 / M HD / CR1 CR obtained only after auto-HCT 3 / 90 28 / M B (1 Al) B (1 Al) 3.6 120
16 49 / M MM / PR 4 prior lines of q including 2 auto-HCT 2 / 90 37 / M 0 C (1 Ag) 8.9 303
17 56 / F AML / CR1 Normal cytogenetics with NPMI unmutated 0 / 90 35 / M C (1 Ag) C (1 Al) 9.2 324
18 64 / F MM / VGPR 6 prior lines of q including 3 auto-HCT 3 / 80 25 / M C (1Ag) C (1 Ag) 9.1 267
19 54 / M DLBCL / CR CR obtained only after auto-HCT 2 / 100 49 / F B (1 Al) B (1 Al) 4.8 314
20 62 / M MM / VGPR 4 prior lines of q including 2 auto-HCT 3 / 90 32 / M C (1 Ag), B (1 Al) C (1 Ag), B (1 Al) 3.1 133
Pt indicates patient; HCT, hematopoietic cell transplantation; HCT-CI, hematopoietic cell transplantation comorbidity index; KS, Karnofsky score; M/M, mismatch; GVHD, graft-versus-host disease; F, female; M, male;
MM, multiple myeloma; CLL, chronic lymphocytic leukemia; AML, acute myelogenous leukemia; PL, plasmoblastic leukemia; NHL-T, T cell non-Hodgkin lymphoma; NHL-F, follicular non-Hodgkin lymphoma; sAML,
secondary AML; PBSC, peripheral blood stem cell; DLBCL, Diffuse large B cell lymphoma; HD, Hodgkin Disease; PR, partial response; CR, complete remission; VGPR, very good partial response; ref, refractory; Ag,
antigen; Al, allele; q, treatment.
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Biol Blood Marrow Transplant 16:838-847, 2010 843MSC after Nonmyeloablative Conditioningcarried out with Graphpad Prism (Graphpad Software,
San Diego, CA) and SAS version 9.1 for Windows
(SAS Institute, Cary, NC).Figure 1. T cell engraftment kinetics (donor T cell chimerism levels) in
MSC patients (white bars) and in historic patients (black bars).RESULTS
Patients and PBSC Donors
Twenty patients were included in the study be-
tween January 2007 and September 2008. Their diag-
noses are listed in Tables 1 and 2. Median patient age
was 58 years (range: 21-69 years), and median HCT-
CI score [43] was 3 (range: 0-9). Contraindication
for myeloablative allogeneic HCT included aged
$55 years (n 5 6), previous autologous HCT (n 5
4), aged $55 years and previous autologous HCT
(n 5 8), and comorbidity (severe mental deficiency
[n5 1], and invasive lung aspergillosis [n5 1]). All pa-
tients were given grafts from unrelated donors. HLA-
compatibility between donor and recipients is de-
scribed in Table 1. Briefly, 13 pairs were mismatched
for at least 1 HLA antigen (including 4 pairs who
were also mismatched for another antigen [n 5 3] or
1 HLA allele [n 5 1]), 1 pair was mismatched for 2
HLA alleles, and 6 pairs were mismatched for a single
HLA class I (n 5 3) or HLA class II (n 5 3) alleles.
Median number of transplanted CD341 and CD31
T cells were 4.8 (range: 1.6-11.8)  106/kg recipients
and 312 (range: 120-540)  106/kg recipients, respec-
tively.Median follow-up for surviving patients was 560
(range: 398-908) days.
Mesenchymal Stem Cells
Before freezing, MSC viability was 93% (range:
90%-97%), whereas CD3 and CD45 were expressed
by\0.01% of the cells, CD80 and CD31 by #1% of
the cells, and CD90, CD105, and CD73 by 99%
(range: 99%-100%), 99% (range: 98%-99%), and
99% (range: 88%-100%) of the cells, respectively.
HLA compatibility between MSC donors, recipients,
and PBSC donors was assessed for 17 of 20 patients.
Number of HLA-antigen mismatches between MSC
donors and recipients were 10 for 1 patient, 9 for 4 pa-
tients, 8 for 6 patients, 7 for 3 patients, 6 for 2 patients,
and 3 for 1 patient. The number of HLA-antigen mis-
matches between MSC donors and PBSC donors were
10 for 1 patient, 9 for 4 patients, 8 for 5 patients, 7 for 4
patients, 6 for 2 patients, and 3 for 1 patient.
NRM (Primary Endpoint)
Two of 20 patients died of nonrelapse causes on
days 74 (cerebral toxoplasmosis in a patient on steroids
as treatment for grade II aGVHD) and 114 (encepha-
lopathy and grade IV aGVHD) after HCT. Day 100
(primary endpoint) and day 365 cumulative incidence
of NRM were 5% and 10%, respectively.Engraftment Kinetics and Graft Rejection
One patient (patient #10, given 10/10HLA-antigen
mismatched MSCs) had primary graft rejection to-
gether with relapse of AML. All remaining patients
had sustained donor T cell engraftment. Median donor
Tcell chimerism levels ondays 28, 40, 100, 180, and 365
were 90%, 91%, 98%, 97%, and 98%, respectively
(Figure 1). Interestingly, 1 patient experiencedgraft fail-
ure despite persistent high donorT cell (98.5%) and to-
tal white blood cell (99.7%) chimerism levels, and no
evidence of disease relapse (but aplastic marrow) on
day 267 after HCT. The patient is currently doing
very well in complete remission without immunosup-
pressive treatment after receiving a second transplant
from another HLA-mismatched donor after condition-
ing with Flu (90 mg/m2) and 4 Gy TBI [46] on day 323
after his first transplant.
Acute GVHD and cGVHD
The 100-day incidence of grade II-IV aGVHDwas
35%, but 2 patients had late aGVHD (after reinduction
chemotherapy [n 5 1], or donor leukocyte infusion
(DLI) [n 5 1]) (Figure 2A). Specifically, grades I, II,
III, and IVaGVHDwere seen in2, 5, 2, and2 (including
the patient who developed GVHD following DLI) pa-
tients, respectively, whereas 2, 5, and 8 patients experi-
enced NIH mild, moderate, and severe cGVHD,
respectively. The 1-year cumulative incidence of mod-
erate or severe cGVHD was 65% (Figure 2B). The 1-
and 2-year probability of dying from GVHD or from
infection while on treatment for GVHD were 10%
and 10%, respectively.
Disease Response and Disease Progression
Three of 7 (43%) patients with measurable disease
at HCT achieved complete remission on days 41, 104,
and 353 after HCT, respectively. Two patients with
AML (including the 1 with primary graft rejection)
and 5 with MM experienced disease progression.
The 1-year cumulative incidence of disease progres-
sion was 30%.
Figure 2. (A) Cumulative incidence of grade II-IV aGVHD in study
patients given MSC (MSC group, broken line) or in historic patients
(solid line). (B) Cumulative incidence of moderate/severe cGVHD in
study patients given MSC (MSC group, broken line) or in historic
patients (solid line).
Figure 3. OS (A) and PFS (B) in study patients given MSC (MSC group,
broken line) or in historic patients (solid line).
844 Biol Blood Marrow Transplant 16:838-847, 2010F. Baron et al.Overall Survival (OS) and Progression-Free
Survival (PFS)
One-year OS and PFS were 80% and 60%, respec-
tively (Figure 3A-B).Comparison with the Historic Group
One of 20 patients in theMSC group versus 0 of 16
patients in the historic group experienced graft rejec-
tion. Median times to achieve 1  109 neutrophils/L
and 100  109 platelets/L were 10 and 11 days in the
MSC group, versus 9 (P 5 .2) and 13 (P 5 .7) days in
the historic group, respectively. Median numbers of
T cells of donor origin on day 28 posttransplant
were 293 (range: 4-540)  106/L in the MSC group
versus 202 (range: 41-886)  106/L in the historic
group. Nine of 20 patients (45%) in the MSC group
versus 9 of 16 patients (56%) in the historic group ex-
perienced grade II-IV aGVHD (Figure 2A). Two of 20
patients (10%) in the MSC group (including 1 patient
after DLI) versus 3 of 16 patients (19%) in the historic
group developed grade IV aGVHD. The 1- and 2-yearprobability of dying fromGVHDor infection while on
treatment for GVHD was 10% and 10%, respectively,
in the MSC group, versus 31% and 38%, respectively,
in the historic group (P 5 .04). One-year nonrelapse
mortality, relapse incidence, OS, and PFS were 10%,
30%, 80%, and 60%, respectively, in the MSC group,
versus 37% (P 5 .02), 25% (P 5 .9), 44% (P 5 .02),
and 38% (P 5 .1) in the historic group (Figure 3A-
B). Within the historic group, 1-year survival and inci-
dence of death from GVHD or infection with GVHD
were 45% and 27%, respectively, in patients given cy-
closporine plus MMF as GVHD prophylaxis (n5 11),
versus 40% and 40% in those given tacrolimus plus
MMF as GVHD prophylaxis (n 5 5). In multivariate
analysis, MSC cotransplantation was significantly as-
sociated with decreased NRM [HR 5 0.2 (95% confi-
dence interval [CI], 0.04-0.9), P 5 .03] and overall
mortality [HR 5 0.4 (95% CI, 0.1-0.9), P 5 .03]
(Table 3).DISCUSSION
Previous studies have shown that MSC coinfusion
might support engraftment of donor hematopoiesis/
lymphopoiesis [35], and prevent severe aGVHD [39].
However, observations in mice and in humans
have suggested that MSCs might abrogate graft-
Table 3. Multivariate Analysis of Factors Affecting Overall Mortality and Nonrelapse Mortality in the MSC and Historic Groups
Combined (n 5 36)
Nonrelapse mortality Mortality
Factor Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Mesenchymal stem cell infusion 0.18 (0.04-0.87) .03 0.35 (0.14-0.90) .03
Patient age 1.0 (0.95-1.0) .9 1.0 (0.99-1.1) .3
Disease-risk (Kahl score) 0.6 (0.27-1.5) .3 1.0 (0.6-1.8) .9
Comorbidity (HCT-CI score) 1.0 (0.69-1.3) .8 1.0 (0.8-1.3) .8
>1 single allele HLA-mismatch 0.7 (0.16-2.8) .6 0.9 (0.4-2.4) .9
CI indicates confidence interval; MSC, mesenchymal stem cell; HCT-CI, hematopoietic cell transplantation comorbidity index.
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lapse [38,39]. Because following NMA conditioning
tumor eradication depends nearly exclusively on
GVT effects [3,14,19], our study offers a unique
opportunity to directly assess the impact of MSC
cotransplantation on GVHD and GVT effects.
The primary endpoint of the study was to investi-
gate whether NMA conditioning followed by cotrans-
plantation of MSCs and HLA-mismatched PBSCs
was safe (defined by a day 100 incidence of nonrelapse
mortality\35%). This objective was largely achieved
as the incidence of nonrelapse mortality was 5% at
day 100, and 10% at 1 year. For comparison, the
1-year nonrelapse mortality was 37% in our historic
group of patients given HLA-mismatched PBSCs,
and ranged from 18% to 29% in other studies analyz-
ing data from patients given HLA-matched unrelated
PBSCs (without MSCs) after Flu and 2 Gy TBI
[1,4,47,48]. The decreased NRM in the MSC group
compared to the historic group is not likely to be
related to the larger use of tacrolimus in the MSC
group than in the historic group, because death
from GVHD or infection was slightly higher in
historic patients given tacrolimus plus MMF than
in those given cyclosporine 1 MMF as GVHD
prophylaxis.
Another important observation was that the rate of
grade IV aGVHD was low in our study, and compara-
ble to what has been observed with patients given
HLA-matched unrelated PBSCs (without MSCs) after
Flu and 2 Gy TBI [1,4,47,48]. Further, the rate of
grade IV aGVHD as well as the incidence of death
from or with GVHD was lower in our MSC group
than in our historic group. These observations
suggest that MSCs might have prevented death from
GVHD in patients given HLA-mismatched PBSCs
from unrelated donors.
A major observation of our study was that MSC
coinfusion did not abrogate GVT effects. Following
NMA conditioning, previous studies have demon-
strated a close relationship between GVT effects and
achievement of full donor T cell/NK cell chimerism
[14,15,17], or occurrence of cGVHD [14,19]. In the
current study, full donor T cell chimerism was
achieved promptly in most patients, whereas 65% ofpatients experienced NIH moderate/severe cGVHD.
Consequently, 43% of patients with measurable
disease achieved a complete remission 41 to 353 days
after HCT (a rate similar to what has been observed
in patients given HLA-matched PBSCs without
MSC coinfusion [14]), whereas the 1-year cumulative
incidence of relapse was 30%, which is similar to
what was observed in our control group.
Finally, we observed a 5% incidence of graft rejec-
tion (0% in the historic group), whereas donor T cell
chimerism levels were similar in the MSC and historic
groups. Further studies are needed to analyze the im-
pact of MSC cotransplantation on chimerism levels
and on the incidence of graft rejection after NMA con-
ditioning, because one could speculate that MSCs
could interfere with graft-versus-host reactions re-
quired to create BM space allowing establishment of
donor hematopoiesis [49]. On the other hand, MSC
might mitigate host-versus-graft rejection mediated
by recipient T cells after NMA conditioning [49,50],
thus promoting engraftment, and/or might mitigate
the production of HLA-antibodies (not assessed in
the current study) that have been associated with graft
rejection after myeloablative HLA-mismatched trans-
plantation [51].
In conclusion, HLA-mismatchedNMAHCTwith
MSC coinfusion appeared to be safe. Furthermore,
MSC coinfusion might have prevented death from
GVHD without abrogating GVT effects. Based on
these encouraging results (that should obviously be
confirmed in a larger number of patients), amulticenter
randomized study of MSC cotransplantation in
patients givenHLA-mismatchedPBSCs after nonmye-
loablative conditioning is being developed in Belgium.ACKNOWLEDGMENTS
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